Please assess the completion status of the following clinical trial:

Trial Title: Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females\* aging ≥ 18 years.~2. Documented HIV infection).~3. Stable antiretroviral treatment for at least 2 weeks prior to enrolment.~4. Optimal adherence to antiretroviral treatment, defined as less than 2 missed doses within the previousweek.~5. End-stage renal disease in renal replacement therapy with periodic hemodialysis.~6. Agree with the study procedures and signature of the informed consent. \*Women of childbearing potential must have a negative pregnancy test prior to randomization into the study and commitment to useat least one of these birth control methods: male or female condom with or without spermicide, cap, diaphragm or sponge with orwithout spermicide, intrauterine device, bilateral tubal occlusion, vasectomized partner, sexual abstinence during the study. Condomuse is considered as an additional method of contraception only and cannot be the only method of contraception used as not beenconsidered an effective method by the Clinical Trial Facilitation Group (CTFG) guidelines.~Based on ICH, M3 (R2) 2009 a woman is considered of childbearing potential: fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include tubal ligation, hysterectomy, bilateral oophorectomy.~Exclusion Criteria:~1. Evidence or clinical suspicion that the patient will not be able to comply with the study protocol.~2. Hypersensitivity to doravirine~3. Concomitant therapy within the previous 4 weeks with any of the following drugs:~   * Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin~  * Androgen receptor inhibitor: enzalutamide~  * Antimycobacterials: rifampin, rifapentine~  * Cytotoxic agent: mitotane~  * St. John's wort (Hypericum perforatum)~4. Females who are pregnant or breastfeeding.~5. ALT and/ or AST ≥ 4 times the upper limit of normal (ULN) at screening.~6. Hemoglobin \< 7,5 g/dL at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Experimental group (Type: EXPERIMENTAL): Doravirine (Pifeltro, MSD) will be added to participant's cART (100 mg once daily) for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).